Peer-reviewed article
NFB-21. Neurofibromatosis Type I in the Setting of Neuro-Oncology
·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This is a medical clinical review about neurofibromatosis type 1 (NF1), a genetic condition that increases cancer risk in children and young adults. The document discusses how specialist nurses coordinate care for NF1 patients with brain tumors and other cancers. It covers the genetic basis of NF1, associated tumor risks, and multidisciplinary care strategies at a tertiary care center.
Key points
- NF1 patients have increased incidence of brain tumors and malignant peripheral nerve sheath tumors (MPNST)
- Most brain tumors in NF1 have good prognosis, but MPNST has extremely poor prognosis
- NF1 patients are more sensitive to chemotherapy and have higher risk of radiation-induced secondary tumors
- Complex care coordination between neuro-oncology and solid tumor teams is required
- Nurses and practitioners need expertise in neuro-oncology, NF1, and solid tumors to provide comprehensive care
Limitations
This is a clinical review and educational resource for healthcare professionals rather than an empirical study evaluating child well-being outcomes. It does not measure the effectiveness of interventions or outcomes for children with NF1.
Abstract
Abstract Neurofibromatosis Type I (NF1) is an autosomal dominant genetic syndrome that is inherited or sporadic. Neuro-Oncology nurses are experienced in the multidisciplinary care of NF1 patients due to an increased incidence of brain tumors and the treatment of plexiform neurofibromas with Mek inhibitors. However, these children are also at higher risk of rare solid tumors, specifically malignant peripheral nerve sheath tumors (MPNST). Most brain tumors in NF1 have a good prognosis. Conversely, MPNST has an extremely poor prognosis. While patients with MPNST are often cared for by solid tumor care teams, the identification and diagnosis of the tumors occur under the care of the neuro-oncology care team. Complex care coordination for patients with NF1 and cancer is required. Specifically, patients with NF1 are more sensitive to chemotherapy, have a higher incidence of radiation-induced secondary tumors, and need monitoring for NF1 related health impacts. Nurses and nurse practitioners with expertise in neuro-oncology, NF1, and solid tumors must collaborate to provide comprehensive care. Teaching tools and clinical strategies have been developed to maintain patients’ continuity with the primary oncology team while gaining the support of subspecialists. The genetic basis, inheritance pattern, and characteristics of Neurofibromatosis Type I will be discussed as well as rare oncologic diagnoses that are more prevalent in children/young adults with NF1. The multidisciplinary approach to the care of the patient with NF1 and a rare cancer diagnoses at a tertiary care center as well as the optimization of care of patients with NF1 and other underlying syndromes and rare cancers will be reviewed. Increased knowledge of NF1 and the associated health impacts and risk of cancers will improve the care of all patients with NF1.